Jun 14, 2023 / 06:20PM GMT
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Good morning. Thanks, everyone, for joining us. I'm Salveen Richter, covered biotechnology at Goldman Sachs, and we're really pleased to have Bob Bradway, Chairman and CEO of Amgen with us. Bob, maybe to start here, a lot of big themes and events that are playing out in health care, especially specifically with relation to biopharma. Perhaps you could start by just talking about the recent FTC move to block your proposed acquisition of Horizon. What are your thoughts on the cross-bundling agreement? How do you expect this to play out? And what gives you confidence that this deal will still close?
Robert A. Bradway - Amgen Inc. - Chairman, CEO & President
Well, first, I'd say we remain very excited about the opportunity of combining with Horizon. So the more we've gotten to know the company and the opportunity, the more enthusiastic we've become about our ability to add value by combining forces with them. So I think in terms of our confidence in the law, we've been very clear, and I
Amgen Inc at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers